Published in
Taylor and Francis Group, Leukemia & Lymphoma, 8(62), p. 1816-1827, 2021
DOI: 10.1080/10428194.2021.1888379
Links
Tools
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study
Journal article published in 2021 by
Sanjal Desai 
,
Clifton Mo,
Erika M. Gaglione,
Constance M. Yuan,
Maryalice Stetler-Stevenson,
Xin Tian,
Irina Maric,
Laura Wake,
Mohammed Z. Farooqui,
Dennis C. Drinkwater,
Susan Soto,
Janet Valdez,
Thomas E. Hughes,
Pia Nierman,
Jennifer Lotter
and other authors.
,
Clifton Mo,
Erika M. Gaglione,
Constance M. Yuan,
Maryalice Stetler-Stevenson,
Xin Tian,
Irina Maric,
Laura Wake,
Mohammed Z. Farooqui,
Dennis C. Drinkwater,
Susan Soto,
Janet Valdez,
Thomas E. Hughes,
Pia Nierman,
Jennifer Lotter
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 